A self-expanding wire frame for a pre-configured compressible transcatheter prosthetic cardiovascular valve, a combined inner frame/outer frame support structure for a prosthetic valve, and methods for deploying such a valve for treatment of a patient in need thereof, are disclosed.

A dry animal-derived collagen fiber tissue material and preparation method and bioprosthesis thereof are disclosed. The preparation method includes: 1) rinsing of an animal-derived collagen fiber tissue material that has been treated with a crosslinking agent; 2) immersion of the rinsed tissue material in a non-aqueous alcoholic solution for dehydration; 3) successive immersion of the tissue material that has been dehydrated with the non-aqueous alcoholic solution in saccharide solutions of different gradients of concentrations for gradient dehydration; 4) taking out and drying of the gradient dehydrated tissue material; and 5) hermetic packaging of the dried tissue material and sterilization. The preparation method is simple and allows the use of easily-available low-cost materials, resulting in lower costs. In addition, it can reduce the toxicity caused by a residue of the aldehyde crosslinking agent. The prepared biological tissue material is pliable and tough, less prone to bending or warping, has a water content that can be well controlled and better biocompatibility due to absence of polyhydric alcohol residues.

A sheet structure comprising two joined extracellular matrix (ECM) tissue or sheet layers and a physiological sensor disposed therebetween; the ECM tissue being derived from a mammalian tissue source that includes small intestine submucosa (SIS), urinary bladder submucosa (UBS), stomach submucosa (SS), urinary basement membrane (UBM), liver basement membrane (LBM), amniotic membrane, mesothelial tissue, placental tissue and cardiac tissue.

The present disclosure relates to methods for producing tissue matrix products with active agents to achieve localized distribution and controlled active agent release. The method can include inserting a carrier element comprising a biodegradable material and active agent into surface features of a tissue matrix product. Also provided are tissue matrix products made using the disclosed methods.

Described are methods and compositions for treatment of reproductive or urogenital mucosal tissue damage using Extracellular Matrix (ECM) solution and, particularly, Extracellular Matrix Hydrogel (ECMH) solution delivered to the target site for tissue repair, restoration, remodeling, or reconstruction.

The present disclosure provides a composite decellularized matrix membrane and use thereof. The composite decellularized matrix membrane prepared by the present disclosure is prepared by wrapping one layer of a polymer membrane with two layers of decellularized matrix membranes. The decellularized matrix membrane is prepared from at least a biomaterial of a porcine small intestine, a porcine bladder, and porcine skin. The polymer membrane is prepared from at least a polymer material of polycaprolactone, polydimethylsiloxane, polyurethane, polylactic acid-glycolic acid, polyvinyl alcohol, and polyhydroxy fatty acid ester. The composite decellularized matrix membrane prepared by the present disclosure can prevent calculi, makes a patient suffer less, recover faster, live better, and cost less, while medical resources are saved, and hope for treatment is also brought for some patients with a contraindication to an in-situ ileal neobladder surgery.

The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment non-soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of non-soft tissue (e.g. bone) when combined with a biocompatible matrix, preferably SIS. The invention further provides methods of using compositions comprising muscle-derived progenitor cells with a biocompatible matrix for the augmentation and bulking of mammalian, including human, bone tissues in the treatment of various functional conditions, including osteoporosis, Paget's Disease, osteogenesis imperfecta, bone fracture, osteomalacia, decrease in bone trabecular strength, decrease in bone cortical strength and decrease in bone density with old age.

Disclosed herein is a continuous tubular shaped valve member formed from crosslinked, acellular pericardium tissue. The tubular shaped valve member can have a lumen, an outer wall, a longitudinal axis, an inlet portion, and an outlet portion, the outlet portion comprising a top edge, wherein said top edge is disposed proximate said inlet portion, the outlet portion defining an outlet in fluid communication with said lumen of said tubular shaped valve member, said inlet portion defining an inlet in fluid communication with said lumen of said tubular shaped valve member.

A method for manufacturing a heart valve using bioprosthetic tissue that exhibits reduced in vivo calcification. The method includes applying a calcification mitigant such as a capping agent or an antioxidant to the tissue to specifically inhibit oxidation in tissue. Also, the method can be used to inhibit oxidation in dehydrated tissue. The capping agent suppresses the formation of binding sites in the tissue that are exposed or generated by the oxidation and otherwise would, upon implant, attract calcium, phosphate, immunogenic factors, or other precursors to calcification. In one method, tissue leaflets in assembled bioprosthetic heart valves are pretreated with an aldehyde capping agent prior to dehydration and sterilization.

An extracellular matrix (ECM) structure for tissue regeneration, the ECM structure having a a sheet member comprising small intestine submucosa (SIS), the SIS sheet member being folded and laminated proximate the sheet member edge, wherein a folded laminated ECM structure having a cavity therein is formed, the ECM structure further including an ECM composition that is disposed in the ECM structure cavity, the ECM composition including liver basement membrane, urinary bladder submucosa, a mesenchymal stem cell and a growth factor.